In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
No Consensus on PMP Company Criteria, Likely Review for Spillover Rule: Chuikyo
To read the full story
Related Article
- Chuikyo Agrees to Scrap Company Indicators to Rank PMP-Eligible Firms
December 14, 2023
- Pharma Industry Backs MHLW Proposal to Scrap PMP Indicators: Chuikyo Hearing
December 7, 2023
- MHLW Proposes Tightening 40% Entry Pricing for New Oral Generics
November 30, 2023
- MHLW Pushes Boosted Launch Premiums, Slew of Other Pricing Steps to Reward Innovation
November 30, 2023
- Chuikyo Reps Split on Nixing PMP Company Criteria; Many Back Review of Reduction Caps under Re-Pricing
November 24, 2023
- Chuikyo at Odds over Handling of Startups in PMP, Timing of Deferred Price Cuts
October 19, 2023
REGULATORY
- LDP Study Group Mulls Seeking More Budget for Immunoglobulins in FY2025
August 30, 2024
- FY2025 Budget Request Earmarks Funding to Systematize Collection of Drug Supply Info
August 30, 2024
- MHLW Seeks 19.8 Billion Yen for Launch of Pandemic Agency JIHS in April
August 30, 2024
- MHLW Requests Funds for Adding PMDA Reviewers, Subsidizing Advisory Fees in FY2025
August 29, 2024
- MHLW to Seek Nearly 800 Million Yen to Boost New Modalities: FY2025 Budget Request
August 29, 2024
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…